Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RIPK1 | Q13546 | 1/20 | 0.74 |
| ▸ | GPR88 | Q9GZN0 | 7/20 | 0.50 |
| ▸ | KCNQ3 | O43525 | 1/20 | 0.49 |
| ▸ | KCNQ2 | O43526 | 1/20 | 0.49 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | ROCK2 | O75116 | 3/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 3/20 | 0.48 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.48 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 0.48 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 1/20 | 0.48 |
| ▸ | PRKCG | P05129 | 1/20 | 0.48 |
| ▸ | CDK1 | P06493 | 1/20 | 0.48 |
| ▸ | PRKACA | P17612 | 1/20 | 0.48 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.48 |
| ▸ | CDK2 | P24941 | 1/20 | 0.48 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.48 |
| ▸ | AKT1 | P31749 | 1/20 | 0.48 |
| ▸ | AKT2 | P31751 | 1/20 | 0.48 |
| ▸ | CLK2 | P49760 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12666568 | 0.90 | RIPK1 (0.74) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL25587390 | 0.90 | RIPK1 (0.74) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL25587388 | 0.90 | RIPK1 (0.74) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL17874150 | 0.85 | RIPK1 (1.00) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL17882274 | 0.85 | RIPK1 (1.00) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL8070440 | 0.83 | RIPK1 (0.65) | RIPK1GPR88KCNQ3KCNQ2 | |
| SCHEMBL2981739 | 0.83 | RIPK1 (0.65) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL2981738 | 0.83 | RIPK1 (0.65) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL9973450 | 0.83 | RIPK1 (0.65) | RIPK1GPR88KCNQ3KCNQ2EPHX2 | |
| SCHEMBL4346530 | 0.82 | GPR88 (0.57) | RIPK1GPR88 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612236-B2 | Method for producing optically active bisamidoalcohol compound | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2009-11-03 | — | — | US | disclosed |
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | SUMITOMO CHEMICAL COMPANY, LIMITED | 2007-05-03 | — | — | US | disclosed |
| EP-1698616-A1 | METHOD FOR PRODUCING OPTICALLY ACTIVE BISAMIDO ALCOHOL COMPOUND | Sumitomo Chemical Company, Limited (JP) | 2006-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070100163-A1 | Reacting an optically active aminoalcohol compound with a diester compound in the presence of a lithium compound wherein the lithium compound is selected from lithium hydroxide, a lithium alkoxide and a lithium halide; product can be efficiently and inexpensively produced | CCNL2, ARL1, ACSL3 | RIPK1 1943/4885GPR88 3058/4885KCNQ3 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.